AVANIR to Present at the Thomas Weisel Partners and the Rodman & Renshaw Healthcare Conferences

ALISO VIEJO, Calif., September 2, 2009 - AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the Company will present at the Thomas Weisel Partners Healthcare Conference and the Rodman & Renshaw 11th Annual Healthcare Conference.

AVANIR will present at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 9th at 3:50 p.m. Eastern time (12:50 p.m. Pacific time) at the Four Seasons Hotel in Boston. The Thomas Weisel Partners Healthcare Conference is a leading industry event attracting over 200 leading public and private healthcare companies. The conference provides participating companies with the opportunity to present to top institutional investors and industry experts.

AVANIR will also present at the Rodman & Renshaw 11th Annual Healthcare Conference on Thursday, September 10th at 10:50 a.m. Eastern time (7:50 a.m. Pacific time) at the New York Palace Hotel in New York City. The Rodman & Renshaw Healthcare Conference provides the opportunity for participating companies to present to institutional investors, venture capitalists, sophisticated private investors, and business development and partnering executives.

A live audio webcast of the presentations will be available by visiting AVANIR's website at www.avanir.com. To listen to the live presentation, please go to AVANIR's website prior to the start of the presentation to register, download and install the necessary software. An archive of the presentation at the Thomas Weisel Partners Healthcare Conference and the Rodman & Renshaw 11th Annual Healthcare Conference will be available on the Company's website.


AVANIR Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders. AVANIR's lead product candidate, Zenvia™, is being developed for the treatment of pseudobulbar affect (PBA) and has successfully completed a Phase III trial for diabetic peripheral neuropathic (DPN) pain. AVANIR has licensed its MIF inhibitor program to Novartis International Pharmaceuticals Ltd. and has sold its anthrax monoclonal antibody program to Emergent BioSolutions. The Company's first commercialized product, Abreva® (docosanol), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com and further information about pseudobulbar affect can be found at www.PBAinfo.org.

To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website:

AVANIR Investor Contacts
Eric Benevich
Brenna Mullen

Sep 02, 2009